2p24 Gain Region Harboring MYCN Gene Compared with MYCN Amplified and Nonamplified Neuroblastoma: Biological and Clinical Characteristics

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2010 Apr 17

PMID 20395439

Citations 17

Authors

Marta Jeison

Shifra Ash

Gili Halevy-Berko

Jacques Mardoukh

Drorit Luria

Smadar Avigad

Galina Feinberg-Gorenshtein

Yacov Goshen

Gabriel Hertzel

Joseph Kapelushnik

Ayelet Ben Barak

Dina Attias

Ran Steinberg

Jerry Stein

Batia Stark

Isaac Yaniv

Affiliations

Soon will be listed here.

Abstract

Although the role of MYCN amplification in neuroblastoma is well established, the biological and clinical characteristics of the 2p gain region harboring the MYCN gene remain unclear. The aim of this study was to compare the biological and clinical characteristics of these tumors with MYCN amplified and nonamplified neuroblastoma and to determine their impact on disease outcome. Samples from 177 patients were analyzed by fluorescence in situ hybridization, including MYCN, 1p, 17q, and 11q regions; 2p gain was identified in 25 patients, MYCN amplification in 31, and no amplification in 121 patients. Patients with 2p gain had a significantly worse 5-year event-free survival rate than patients with no MYCN amplified (P < 0.001), and an intermediate 5-year overall survival rate difference existed between the MYCN amplified tumors (P = 0.025) and nonamplified (P = 0.003) groups. All of the 2p gain samples were associated with segmental and/or numerical alterations in the other tested regions. The presence of segmental alterations with or without MYCN amplification was recently found to be the strongest predictor of relapse in a multivariate analysis. The results of the present study suggest that the determination of MYCN gene copy number relative to chromosome 2, when evaluating MYCN status at diagnosis, may help to reveal the underlying genetic pattern of these tumors and better understand their clinical behavior.

Citing Articles

Segmental chromosome aberrations as a prognostic factor of neuroblastoma: a meta-analysis and systematic review.

Geng J, Wang X, Zhao L, Zhang J, Niu H Transl Pediatr. 2024; 13(10):1789-1798.

PMID: 39524401 PMC: 11543117. DOI: 10.21037/tp-24-200.

Application of the FISH method and high-density SNP arrays to assess genetic changes in neuroblastoma-research by one institute.

Winnicka D, Skowera P, Stelmach M, Styka B, Lejman M Acta Biochim Pol. 2024; 71:12821.

PMID: 39049899 PMC: 11267511. DOI: 10.3389/abp.2024.12821.

F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) imaging of pediatric neuroblastoma: a multi-omics parameters method to predict MYCN copy number category.

Qian L, Zhou Z, Li S, Liu J, Zhang S, Ren J Quant Imaging Med Surg. 2024; 14(4):3131-3145.

PMID: 38617169 PMC: 11007507. DOI: 10.21037/qims-23-494.

17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications.

Mlakar V, Dupanloup I, Gonzales F, Papangelopoulou D, Ansari M, Gumy-Pause F Cancers (Basel). 2024; 16(2).

PMID: 38254827 PMC: 10814316. DOI: 10.3390/cancers16020338.

The Regulatory Mechanisms and Clinical Significance of Lnc SNHG4 in Cancer.

Pourghasem N, Ghorbanzadeh S, Nejatizadeh A Curr Pharm Des. 2022; 28(44):3563-3571.

PMID: 36411578 DOI: 10.2174/1381612829666221121161950.

References

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Bown N, Cotterill S, Lastowska M, ONeill S, Pearson A, Plantaz D . Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340(25):1954-61. DOI: 10.1056/NEJM199906243402504. View

Noguera R, Canete A, Pellin A, Ruiz A, Tasso M, Navarro S . MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet. 2003; 140(2):157-61. DOI: 10.1016/s0165-4608(02)00677-5. View

Lastowska M, Cotterill S, Pearson A, Roberts P, McGuckin A, Lewis I . Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. Eur J Cancer. 1997; 33(10):1627-33. DOI: 10.1016/s0959-8049(97)00282-7. View

Valent A, Guillaud-Bataille M, Farra C, Lozach F, Spengler B, Terrier-Lacombe M . Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors. Cancer Genet Cytogenet. 2004; 153(1):10-5. DOI: 10.1016/j.cancergencyto.2003.12.007. View

Mosse Y, Greshock J, Weber B, Maris J . Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era. Cancer Lett. 2005; 228(1-2):83-90. DOI: 10.1016/j.canlet.2005.02.052. View

Lastowska M, van Roy N, Bown N, Speleman F, Lunec J, Strachan T . Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. Genes Chromosomes Cancer. 1998; 23(2):116-22. DOI: 10.1002/(sici)1098-2264(199810)23:2<116::aid-gcc4>3.0.co;2-5. View

Hogarty M, Brodeur G . Wild-type sequence of MYCN in neuroblastoma cell lines. Int J Cancer. 1999; 80(4):630-1. DOI: 10.1002/(sici)1097-0215(19990209)80:4<630::aid-ijc24>3.0.co;2-7. View

van Roy N, Van Limbergen H, Vandesompele J, Van Gele M, Poppe B, Laureys G . Chromosome 2 short arm translocations revealed by M-FISH analysis of neuroblastoma cell lines. Med Pediatr Oncol. 2000; 35(6):538-40. DOI: 10.1002/1096-911x(20001201)35:6<538::aid-mpo8>3.0.co;2-c. View

10.

Bown N, Lastowska M, Cotterill S, ONeill S, Ellershaw C, Roberts P . 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol. 2001; 36(1):14-9. DOI: 10.1002/1096-911X(20010101)36:1<14::AID-MPO1005>3.0.CO;2-G. View

11.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

12.

Ambros I, Benard J, Boavida M, Bown N, Caron H, Combaret V . Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003; 21(11):2077-84. DOI: 10.1200/JCO.2003.03.025. View

13.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

14.

Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D . Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27(7):1026-33. DOI: 10.1200/JCO.2008.16.0630. View

15.

Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C . Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene. 2007; 26(53):7432-44. DOI: 10.1038/sj.onc.1210552. View

16.

Schouten J, McElgunn C, Waaijer R, Zwijnenburg D, Diepvens F, Pals G . Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30(12):e57. PMC: 117299. DOI: 10.1093/nar/gnf056. View

17.

Stallings R, Carty P, McArdle L, Mullarkey M, McDermott M, Breatnach F . Molecular cytogenetic analysis of recurrent unbalanced t(11;17) in neuroblastoma. Cancer Genet Cytogenet. 2004; 154(1):44-51. DOI: 10.1016/j.cancergencyto.2004.04.003. View

18.

Chen Y, Takita J, Choi Y, Kato M, Ohira M, Sanada M . Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008; 455(7215):971-4. DOI: 10.1038/nature07399. View

19.

Savelyeva L, Schwab M . Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett. 2001; 167(2):115-23. DOI: 10.1016/s0304-3835(01)00472-4. View

20.

Schwab M . Oncogene amplification in solid tumors. Semin Cancer Biol. 1999; 9(4):319-25. DOI: 10.1006/scbi.1999.0126. View